$ALNY insider trading
Over the last 12 months, Alnylam Pharmaceuticals insiders reported no purchases and 34 sales totaling $53.7M across SEC Form 4 filings. 47% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $53.7M 34 events
- Events · 12m
- 34 Form 4 filings, grouped
- Insiders · 12m
- 7 distinct reporters
- 10b5-1 share
- 47% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | PYOTT DAVID E ID | ▼ Sale | 17 | $302.65 | $5K | -1.1% | plan |
| Jun 1, 2026 | PYOTT DAVID E ID | ▼ Sale | 495 | $300.72 | $149K | -23.6% | plan |
| Jun 1, 2026 | PYOTT DAVID E ID | ▼ Sale | 1,222 | $299.87 | $366K | -36.9% | plan |
| Jun 1, 2026 | PYOTT DAVID E ID | ▼ Sale | 1,175 | $298.91 | $351K | -26.2% | plan |
| Jun 1, 2026 | PYOTT DAVID E ID | ▼ Sale | 921 | $297.71 | $274K | -17% | plan |
| Apr 6, 2026 | McLaughlin MelissaChief Human Resources Officer · O | ▼ Sale | 3,910 | $325.92 | $1.3M | -29.3% | plan · 14 tranches |
| Mar 5, 2026 | Garg PushkalEVP Chief R&D · O | ▼ Sale | 4,713 | $323.53 | $1.5M | -20.1% | plan · 12 tranches |
| Mar 5, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research · O | ▼ Sale | 1,291 | $323.54 | $418K | -5.9% | plan · 12 tranches |
| Mar 4, 2026 | Greenstreet YvonneChief Executive Officer · O·D | ▼ Sale | 2,933 | $323.08 | $948K | -3% | 8 tranches |
| Mar 4, 2026 | Poulton Jeffrey V.EVP, Chief Financial Officer · O | ▼ Sale | 2,468 | $323.08 | $797K | -3.8% | 8 tranches |
| Mar 4, 2026 | Tanguler TolgaEVP, Chief Commercial Officer · O | ▼ Sale | 2,309 | $323.08 | $746K | -6.3% | 8 tranches |
| Mar 3, 2026 | Garg PushkalEVP Chief R&D · O | ▼ Sale | 3,492 | $323.63 | $1.1M | -13% | plan · 14 tranches |
| Mar 3, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research · O | ▼ Sale | 3,250 | $323.62 | $1.1M | -12.9% | plan · 14 tranches |
| Mar 2, 2026 | Poulton Jeffrey V.EVP, Chief Financial Officer · O | ▼ Sale | 2,206 | $327.65 | $723K | -3.3% | 10 tranches |
| Mar 2, 2026 | Tanguler TolgaEVP, Chief Commercial Officer · O | ▼ Sale | 1,598 | $327.65 | $524K | -4.2% | 10 tranches |
| Mar 2, 2026 | Greenstreet YvonneChief Executive Officer · O·D | ▼ Sale | 6,799 | $327.65 | $2.2M | -6.4% | 10 tranches |
| Feb 27, 2026 | Garg PushkalEVP Chief R&D · O | ▼ Sale | 4,627 | $331.34 | $1.5M | -17.3% | plan · 5 tranches |
| Feb 17, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research · O | ▼ Sale | 4,000 | $321.24 | $1.3M | -15.8% | plan · 2 tranches |
| Feb 13, 2026 | Garg PushkalEVP Chief R&D · O | ▼ Sale | 2,242 | $310.08 | $695K | -8.3% | — |
| Feb 13, 2026 | Greenstreet YvonneChief Executive Officer · O·D | ▼ Sale | 6,958 | $310.08 | $2.2M | -7.5% | — |
| Feb 13, 2026 | Tanguler TolgaEVP, Chief Commercial Officer · O | ▼ Sale | 1,959 | $310.08 | $607K | -5.8% | — |
| Feb 13, 2026 | Poulton Jeffrey V.EVP, Chief Financial Officer · O | ▼ Sale | 2,242 | $310.08 | $695K | -3.6% | — |
| Jan 13, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research · O | ▼ Sale | 3,800 | $367.37 | $1.4M | -15.2% | plan · 27 tranches |
| Jan 12, 2026 | Garg PushkalEVP Chief R&D · O | ▼ Sale | 1,510 | $362.87 | $548K | -6.3% | 21 tranches |
| Jan 12, 2026 | Greenstreet YvonneChief Executive Officer · O·D | ▼ Sale | 9,577 | $362.86 | $3.5M | -10.9% | 21 tranches |
| Jan 12, 2026 | Poulton Jeffrey V.EVP, Chief Financial Officer · O | ▼ Sale | 2,780 | $362.87 | $1.0M | -4.6% | 21 tranches |
| Jan 12, 2026 | Tanguler TolgaEVP, Chief Commercial Officer · O | ▼ Sale | 1,510 | $362.87 | $548K | -4.8% | 21 tranches |
| Nov 17, 2025 | Fitzgerald Kevin JosephCSO & EVP, Head of Research · O | ▼ Sale | 12,128 | $452.18 | $5.5M | -36.3% | plan · 11 tranches |
| Nov 13, 2025 | Greenstreet YvonneChief Executive Officer · O·D | ▼ Sale | 25,650 | $452.75 | $11.6M | -28.2% | plan · 20 tranches |
| Oct 3, 2025 | Garg PushkalEVP Chief R&D · O | ▼ Sale | 5,959 | $451.76 | $2.7M | -22.8% | plan · 17 tranches |
| Oct 2, 2025 | Poulton Jeffrey V.EVP, Chief Financial Officer · O | ▼ Sale | 3,821 | $452.05 | $1.7M | -6.6% | 12 tranches |
| Oct 2, 2025 | Greenstreet YvonneChief Executive Officer · O·D | ▼ Sale | 8,924 | $452.05 | $4.0M | -12% | 12 tranches |
| Oct 2, 2025 | Tanguler TolgaEVP, Chief Commercial Officer · O | ▼ Sale | 1,405 | $452.05 | $635K | -4.9% | 12 tranches |
| Oct 2, 2025 | Fitzgerald Kevin JosephCSO & EVP, Head of Research · O | ▼ Sale | 2,441 | $452.05 | $1.1M | -8.8% | 12 tranches |
| Sep 9, 2025 | Reitan Colleen FD | ▼ Sale | 18,000 | $467.6 | $8.4M | -95.9% | plan · 16 tranches |
| Aug 29, 2025 | Tanguler TolgaEVP, Chief Commercial Officer · O | ▼ Sale | 3,474 | $448.37 | $1.6M | -11.8% | plan · 6 tranches |
| Aug 19, 2025 | Garg PushkalEVP Chief R&D · O | ▼ Sale | 2,851 | $455.89 | $1.3M | -12.4% | plan · 14 tranches |
| Aug 18, 2025 | Tanguler TolgaEVP, Chief Commercial Officer · O | ▼ Sale | 1,396 | $453.27 | $633K | -4.5% | 8 tranches |
| Aug 18, 2025 | Poulton Jeffrey V.EVP, Chief Financial Officer · O | ▼ Sale | 2,274 | $453.27 | $1.0M | -4.3% | 8 tranches |
| Aug 18, 2025 | Greenstreet YvonneChief Executive Officer · O·D | ▼ Sale | 6,979 | $453.27 | $3.2M | -11% | 8 tranches |
| Aug 18, 2025 | Fitzgerald Kevin JosephCSO & EVP, Head of Research · O | ▼ Sale | 1,396 | $453.27 | $633K | -5.8% | 8 tranches |
| Aug 18, 2025 | BONNEY MICHAEL WD | ▼ Sale | 11,250 | $450 | $5.1M | -40.1% | plan |
| Aug 14, 2025 | Ausiello Dennis AD | ▼ Sale | 31,448 | $436.58 | $13.7M | -97.2% | plan · 11 tranches |
Every $ALNY filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Alnylam Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ALNY feed.